Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
Sodium glucose cotransporter 2 inhibitors (SGLT2i) block the reabsorption of glucose by inhibiting SGLT2, thus improving glucose control by promoting the renal excretion of glucose, without requiring insulin secretion. This pharmacological property of SGLT2i reduces body weight and improves insulin...
Main Authors: | Hidekatsu Yanai, Mariko Hakoshima, Hiroki Adachi, Hisayuki Katsuyama |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/9/4416 |
Similar Items
-
Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
by: Ryuhei Sano, et al.
Published: (2020-07-01) -
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
by: Boyang Xiang, et al.
Published: (2021-04-01) -
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01) -
Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
by: Fan Yang, et al.
Published: (2020-12-01) -
Sodium-glucose cotransporter 2 inhibitor use: A pharmaco-ergonomic qualification tool
by: Sanjay Kalra, et al.
Published: (2017-01-01)